Wound Care Biologics Market – Experience the Power of Effective Healing
Wound care biologics are bioengineered products used for non-healing wounds of the lower extremity. Demand for wound care biologic products is expected to increase significantly as early intervention of diabetic ulcer can prevent severe complications such as infection, hospitalization, and amputation. Wound care biologics market is expected to gain significant traction, as the commercially available skin substitutes have clinical and experimental evidence of efficacy in wound healing.
The global wound care biologics market was valued at US$ 1.2 billion in 2016 and is expected to exhibit a robust CAGR of 6.9% over the forecast period (2017–2025).
To get holistic SAMPLE of the report, please click: https://www.coherentmarketinsights.com/insight/request-sample/1506
High prevalence of diabetes is expected to aid in growth of the market
The wound care biologics market is expected to gain significant traction, with rise in global prevalence of diabetes, as diabetic patients are prone to developing diabetic ulcers. According to the Global Diabetes Community, 2017, an estimated 422 million adults are living with diabetes globally, and this is expected to increase to 642 million by 2040. Also, according to the Journal of Foot and Ankle Surgery, 2016, increasing number of diabetic patients has led to increased burden of diabetic complications, where peripheral neuropathy, foot ulceration, and Peripheral Arterial Disease (PAD) is twice as common for diabetic patients as compared to non-diabetics, affecting 30% of the diabetics aged 40 years and above. The Advances in Wound Care Journal, 2015, also stated that 15%–20% of the diabetic population is likely to develop chronic, non-healing foot wounds. Thus, wound care biologic products provides patients with a cost effective option for managing chronic wounds, thereby reducing economic burden of the patients.
However, high cost of skin substitutes and related biologics is a major hindrance for growth of the market. For instance, according to the Advances in Skin Substitutes Journal, 2014, cost for each 1% body surface area covered with Epicel, is estimated to be over US$ 13,000. This in turn, leads to increasing adoption of alternative and cost effective wound care products, which is expected to negatively affect growth of the market.
Asia Pacific market to exhibit fastest growth over the forecast period
Asia Pacific is expected to exhibit significant growth in the global wound care biologics market over the forecast period. This is owing to high prevalence of diabetic patients in Asian countries. According to the Indian Diabetes Research Foundation, 2016, around 60% of the world’s population suffering from diabetes lives in Asia, with around one-half in China and India combined. The Foundation also states that Western Pacific reported over 138.2 million people suffering from diabetes, the number for which is expected to rise to 201.8 million by 2035.
Moreover, rising medical tourism in Asia Pacific is a major driver for growth of the market. The number of foreign patients is increasing, owing to affordable treatment facilitates at hospitals for wound care management. According to the survey by Brink Global Risk Center, 2017, around 4 million medical tourists traveled to India for health care services, 3.5 million foreign patients travelled to Thailand and 900,000 patients to Singapore in 2016, with the number expected to grow by 10%–14% by 2020.
Increasing incidence of chronic wounds and ulcers to accelerate the market growth
Chronic wounds have a significant impact on the health and quality of life of patients and their families, causing pain, emotional stress, restriction on daily activities, depression, distress, and anxiety, with prolonged hospital stay and chronic morbidity. According to the Advances in Wound Care Journal, 2015, chronic leg and foot ulcers last for around 12 months on an average, with recurrence affecting up to 65% of patients, leading to loss of function and decreased quality of life. It is also a significant cause of morbidity. Rising incidence of traumatic events such as accidents and fire accidents causing burns, systemic illness, antibiotic resistant, chronic disease, surgery, and impaired mobility are the prevailing factors resulting in increasing incidence of chronic wounds. The World Health Organization (WHO) also states that burns are the leading cause of morbidity, including prolonged hospitalization, disfigurement, and disability-adjusted life-years (DALYs) lost in low- and middle-income countries. Therefore, these factors are expected to be major factor aiding ion growth of the market over the forecast period.
Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/1506
North America is expected to be dominant region in the wound care biologics market, owing to rising prevalence of chronic non-healing wounds which pose an economic burden to the healthcare system. According to the American Diabetes Association, 2016, the average cost of healing a single foot ulcer is US$ 8,000 and that of a major amputation is $45,000. Furthermore, venous leg ulcers are the most common wound type in the U.S., affecting almost 2 million people.
Major players operating in the global wound care biologics market are Smith & Nephew Plc., Organogenesis, Inc., Integra Lifesciences Holdings Corporation, Skye Biologics, Alphatec Holdings, Inc., Solsys Medical LLC, Amino Technology LLC, and Osiris Therapeutics, Inc.
Cast removal devices are designed to cut cast material such as fiberglass, plastic or plaster and bandage that are used for rehabilitation of the fractured bones or ruptured tendons. It is mainly used by orthopedic surgeons in hospitals and clinics to cure musculoskeletal injuries caused due to road accidents and during sports practices. According to the U.S. Department of Health & Human Services report on January 2018, road traffic injuries are a huge economic burden on low and middle income economies and are estimated to cost US$ 518 billion globally. In many areas in the emerging economies, technology has still not found there roots to grow and people use home remedies such as securing with wooden sticks instead of casting plaster. The development of hospital facilities in these areas will drive growth of cast removal device market. In November 2016, Stryker Corporation, one of the world’s leading medical technology company, announced a multi-year collaboration with Indo UK Institute of Health’s (IUIH) Medicity Program to serve greater access to affordable services to patients in India, which will also help in propelling growth of cast removal device market.
To understand Research Methodology, please click: https://www.coherentmarketinsights.com/insight/request-sample/1493
Cast Removal Device Market Taxonomy:
By Product Type:
Vacuum cutter
Saw cutter
Cast spreader
By Energy Source:
Battery powered (cordless)
Electric (corded)
By End Users:
Clinics
Hospitals
Rehabilitation centers
Other
Cast Removal Device Market Driver
Increase in frequency of road accidents and musculoskeletal injuries during sports is expected to drive growth of the cast removal devices market. According to a survey published by the World Health Organization (WHO) in Jan, 2018, over 3,400 people die on the world’s roads every day and tens of millions of people are injured or disabled every year. Also, according to the John Hopkin’s Medicine, in the U.S., over 3.5 million children at the age of 14 and younger get hurt annually by playing sports or participating in recreational activities.
The upcoming 2030 Agenda for Sustainable Development adopted by world leaders aims at halving the global number of deaths and injuries from road traffic crashes by 2020. Moreover, from 2015-2019, the World Health Organization is collaborating with the Bloomberg Initiative for Global Road Safety (BIGRS) to reduce fatalities and injuries from road traffic crashes. Such forthcoming schemes of the governmental organizations will hinder growth of cast removal devices market, whereas people neglecting traffic rules or distracted driving because of alcohol and other abuse, unsafe road infrastructure, below mark vehicle quality, and many others factors are expected to propel the cast removal device market growth.
The strategies adopted by key market players to come up with innovative technologies such as noise free or debris free plaster cutters at affordable rates are lucrative opportunities for growth of the cast removal device market. Cast removal devices are scary and traumatic for most of the patients due to noise and blade rotation, however, OrthoPediatrics’s Quiet cast removal device was a major leap forward in technology in 2009. Shanghai Bojin Medical instrument Co., Ltd. aimed at coming up with products and solutions with reduced medical costs and lessening the financial burden of the patients. The companies also aims at providing after sales services to the end users, which will propel growth of cast removal devices market. Moreover, cast saws can produce thermal injury or abrasions during cast removal, compromising patient care and can result in litigation. The advancement for avoiding cast-saw burns will also enhance the growth of cast removal device market.
Have a doubt? Speak to our analyst now! https://www.coherentmarketinsights.com/insight/talk-to-analyst/1493
Cast Removal Devices Market – Regional Analysis
The global cast removal market is regionally segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds the dominant position in cast removal device market due to local manufacturers and high incidence of road injuries. For instance, according to the Association for Safe International Road Travel, in 2016, 2.35 million people were injured or disabled every year due to road crash in the U.S. Asia Pacific is expected to be fastest growing market over the forecast period due to increasing prevalence of road accidents. For instance, according to the National Crime Records Bureau, the number of road accidents in 2008 was 415 thousands, which increased to 440 thousands by 2012 in India.
Cosmetic surgeries can do wonders for people who aren’t happy with their current looks and overall appearance. Cosmetic surgeries are safe, reliable and one of the best options to look beautiful for a long time.
Cosmetic surgeries have varying recovery time periods. However, many patients wish to speed up the recovery time, so they can return to their usual lifestyle ASAP.
Here are 5 tips that can help patients to accelerate their recovery period.
1. There’s No Need To Push Through The Pain
If you’re encountering pain after the surgery, it is imperative to take the medicines given by your surgeon. Numerous patients will try unnecessarily to be “strong” and go through the pain, but it is imperative to control pain by taking the precautions and not giving it a chance to affect you severely.
Remember, blood pressure might rise due to extreme pain, and at times this could result in more bruising, which postpones recovery time. Furthermore, it is crucial to stay away from over-the-counter medicines. Consult your surgeon immediately if you feel extreme pain after the surgery.
2. Move On
Ensure that you get lots of rest in the first two or three days post-surgery. However, it doesn’t mean that you have to just constantly lie on the bed and do nothing. In case, you don’t feel like going out for a walk outdoors, you can still move around in your house or garden area to take some fresh air instead of doing nothing. Proper movement helps the body to recover at a good speed, and may also reduce the pain. It additionally reduces some common symptoms of prescribed painkiller medicines.
3. Avoid Workout
Many people are quite health conscious and want to return to their usual exercise routines quite quickly. However, you need to stay away from any form of exercise until the recovery period is completed. Even after getting full recovery it is imperative to do low intensity workout that doesn’t jeopardize the results of your surgery. If you’ve undergone a major cosmetic procedure like a breast surgery, then for the initial 4 weeks, it is essential to avoid being excessively active.
4. Wear Your Compression Garments
You may need to wear compression garment after some surgeries such as breast reduction surgery or breast enlargement surgery. By compressing the tissues, swelling and bruising is controlled by compression garments. This enables the patient’s body to reabsorb collected edema liquid. It also assists in contouring by stopping skin wrinkling and improving skin retraction. The appearance of the scars has often been significantly reduced due to pressure. Compression garments can make the scar flatter and less visible.
5. Say No To Alcohol & Smoking
All the cosmetic surgeons will ask you to stop consumption of alcohol and tobacco a few weeks before and after the surgery. Alcohol and smoking may have adverse effects on the outcomes of many cosmetic procedures like, Botox treatment. So, you need to stay away from these bad habits for some weeks before and after the cosmetic surgery.
Hepatitis C virus is a blood-borne virus that infects liver cells, resulting in illness that ranges from mild and transient effects such as easy bleeding, fatigue, yellow discoloration of skin and eyes, and others to chronic and serious life-threatening conditions such as liver cirrhosis, liver cancer or liver failure. Hepatitis C virus is transmitted through needlestick injuries, organ transplant from a carrier, sexually or from infected mother to fetus. Globally, hepatitis C virus exists in six distinct forms based on its genotypes amongst which Type 1 is the most common form representing around 60 -70 per cent of global infections. Hepatitis C is diagnosed by blood tests for estimating viral load and genotyping, and liver damage tests such as magnetic resonance elastography (MRE), transient elastography, and liver biopsy. Antiviral drugs, which inhibits protease or polymerase enzyme of virus is one of the treatments available for infection caused due to hepatitis C. Currently, no vaccines are available for the prevention of hepatitis C virus and this provides scope for the market players to expand their company portfolio.
Hepatitis C drug market Taxonomy
By Drug Class
Hepatitis C Virus Protease Inhibitor
Glecaprevir
Grazoprevir
Paritaprevir
Simeprevir
Voxilaprevir
Nucleoside/tide Polymerase Inhibitors
Sofosbuvir
NS5A Inhibitors
Daclatasvir
Elbasvir
Ledipasvir
Ombitasvir
Pibrentasvir
Velpatasvir
Non-Nucleoside Polymerase Inhibitors
Dasabuvir
Interferon
Combinational drug
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Hepatitis C drug market Driver
According to the World Health Organization (WHO), in 2017, around 71 million people were infected by chronic hepatitis C worldwide. Furthermore, WHO considers Eastern Mediterranean and European regions to be the most affected regions with the prevalence rate of 2.3% and 1.5% respectively. According to the Centers for Disease Control and Prevention, around 2.7 million to 3.9 million people in the U.S. suffer from hepatitis C. This increasing prevalence of hepatitis C will drive growth of hepatitis C drug market. Furthermore, this blood- borne virus is easily transmitted by sharing injection equipment, transfusion of infectious blood, sexually or from infected mother to infant, which will further propel growth of hepatitis C drug market.
Have a doubt? Speak to our analyst now! https://www.coherentmarketinsights.com/insight/talk-to-analyst/1489
The governmental initiatives for patients to receive expanded drug coverage is also expected to drive growth of the market. For instance, in 2018, the Ministry of Health and Long-Term Care of Ontario announced that all patients are eligible for Ontario Drug Benefit (ODP) irrespective of severity of their disease. In the same year, Thunder Bay group, HIV / AIDS / hepatitis C education and support services provider, expanded its access to medicines, as a result of successful negotiations between the provinces and drug manufacturers.
There are significant number of drugs available for Hepatitis C over the past few years and is expected to increase over the forecast period due to large number of drugs in pipeline. Hepatitis C drug market is revolutionized by direct acting antivirals (DAAs), which aid in the development of highly effective, INF-free hepatitis C drug regimen in contrast to standard treatment. The pipeline consists of dual as well as triple DDA combinational therapy against hepatitis C virus. A combination of drugs is more effective for the treatment of hepatitis C as compared to single regimen. For instance, in 2016, Gilead submitted a new drug application to the U.S. FDA for the fixed-dose combination SOF/VEL/voxilaprevir for treatment of HCV genotypes 1–6. Moreover, in January 2017, EMA granted assessment of SOF/VEL/voxilaprevir combination. Furthermore, in 2017, the U.S. FDA approved AbbVie’s Mavyret, a combination of glecaprevir and pibrentasvir for the treatment of hepatitis C. Hepatitis C drug market is hindered due to high medication cost and denial for Medicaid patients.